Ann Lab Med.  2016 Mar;36(2):124-130. 10.3343/alm.2016.36.2.124.

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii

Affiliations
  • 1Department of Laboratory Medicine, College of Medicine, Chosun University, Gwangju, Korea. sjbjang@chosun.ac.kr
  • 2Research Center for Resistant Cells, College of Medicine, Chosun University, Gwangju, Korea.
  • 3Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea. kscpjsh@yuhs.ac
  • 4Premedical Science, College of Medicine, Chosun University, Gwangju, Korea.

Abstract

BACKGROUND
Acinetobacter baumannii infections are difficult to treat owing to the emergence of various antibiotic resistant isolates. Because treatment options are limited for multidrug-resistant (MDR) A. baumannii infection, the discovery of new therapies, including combination therapy, is required. We evaluated the synergistic activity of colistin, doripenem, and tigecycline combinations against extensively drug-resistant (XDR) A. baumannii and MDR A. baumannii.
METHODS
Time-kill assays were performed for 41 XDR and 28 MDR clinical isolates of A. baumannii by using colistin, doripenem, and tigecycline combinations. Concentrations representative of clinically achievable levels (colistin 2 microg/mL, doripenem 8 microg/mL) and achievable tissue levels (tigecycline 2 microg/mL) for each antibiotic were used in this study.
RESULTS
The colistin-doripenem combination displayed the highest rate of synergy (53.6%) and bactericidal activity (75.4%) in 69 clinical isolates of A. baumannii. Among them, thedoripenem-tigecycline combination showed the lowest rate of synergy (14.5%) and bacteri-cidal activity (24.6%). The doripenem-tigecycline combination showed a higher antagonistic interaction (5.8%) compared with the colistin-tigecycline (1.4%) combination. No antagonism was observed for the colistin-doripenem combination.
CONCLUSIONS
The colistin-doripenem combination is supported in vitro by the high rate of synergy and bactericidal activity and lack of antagonistic reaction in XDR and MDR A. baumannii. It seems to be necessary to perform synergy tests to determine the appropri-ate combination therapy considering the antagonistic reaction found in several isolates against the doripenem-tigecycline and colistin-tigecycline combinations. These findings should be further examined in clinical studies.

Keyword

Extensively drug-resistant; Synergism; Antagonism; Acinetobacter baumannii; Colistin; Doripenem; Tigecycline

MeSH Terms

Acinetobacter Infections/drug therapy/microbiology
Acinetobacter baumannii/*drug effects/genetics/isolation & purification
Anti-Bacterial Agents/*pharmacology/therapeutic use
Bacterial Proteins/genetics
Carbapenems/*pharmacology/therapeutic use
Colistin/*pharmacology/therapeutic use
Drug Resistance, Multiple, Bacterial/*drug effects
Drug Synergism
Drug Therapy, Combination
Humans
Microbial Sensitivity Tests
Minocycline/*analogs & derivatives/pharmacology/therapeutic use
Multilocus Sequence Typing
beta-Lactamases/genetics
Anti-Bacterial Agents
Bacterial Proteins
Carbapenems
Colistin
Minocycline
beta-Lactamases
Full Text Links
  • ALM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error